Influence of plasma expansion on plasma protein binding of ketorolac

Dietrich Gravenstein, Ajit Suri, Hartmut C. Derendorf, Adolph Koska

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Study Objective: To determine the effect of dilution with intravascular volume expanders commonly used by anesthesiologists on clinically relevant levels of free serum ketorolac. Design: In vitro study. Setting: Pharmaceutics laboratory of a medical college. Interventions: The effect of 6% hydroxyethylstarch, 5% albumin, 6% dextran 60, and lactated Ringer's solution on in vitro plasma protein binding of ketorolac was investigated by ultrafiltration. The binding was studied at three different drug concentrations: low therapeutic (0.3 μg/ml), high therapeutic (3 μg/ml), and toxic (10 μg/ml), and at two or more volume expander dilutions. Measurements and Main Results: The effect of plasma dilution on free ketorolac was consistent across all volume expanders tested and for each ketorolac concentration studied. As the plasma dilution with albumin, hydroxyethylstarch, dextran 60, or lactated Ringer's solution increased, the unbound ketorolac also increased from 3.2% to 3.3% in undiluted plasma to 5.0% to 8.7% in 50% dilution of the plasma with the investigated expanders. Dilution of plasma by only 10% resulted in a significant, but relatively minor, increase of unbound ketorolac to 3.2% to 3.8%. Conclusion: Because of the pharmacokinetic properties of ketorolac, this pharmacokinetic interaction can be expected to have only minor effects on unbound ketorolac concentrations when ketorolac is administered after the plasma expander. When ketorolac administration is followed by rapid plasma expander infusion, a transient increase of unbound ketorolac in plasma can be expected.

Original languageEnglish (US)
Pages (from-to)464-468
Number of pages5
JournalJournal of Clinical Anesthesia
Volume10
Issue number6
DOIs
StatePublished - Sep 1998

Fingerprint

Ketorolac
Protein Binding
Blood Proteins
Dextrans
Albumins
Pharmacokinetics
Poisons
Ultrafiltration
Pharmaceutical Preparations

Keywords

  • Albumin
  • Dextran 60
  • Hydroxyethylstarch
  • Ketorolac
  • Plasma
  • Protein binding
  • Ringer's solution, lactated

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Influence of plasma expansion on plasma protein binding of ketorolac. / Gravenstein, Dietrich; Suri, Ajit; Derendorf, Hartmut C.; Koska, Adolph.

In: Journal of Clinical Anesthesia, Vol. 10, No. 6, 09.1998, p. 464-468.

Research output: Contribution to journalArticle

Gravenstein, Dietrich ; Suri, Ajit ; Derendorf, Hartmut C. ; Koska, Adolph. / Influence of plasma expansion on plasma protein binding of ketorolac. In: Journal of Clinical Anesthesia. 1998 ; Vol. 10, No. 6. pp. 464-468.
@article{7be06f0a57e242bb8dedbc0632d6fc97,
title = "Influence of plasma expansion on plasma protein binding of ketorolac",
abstract = "Study Objective: To determine the effect of dilution with intravascular volume expanders commonly used by anesthesiologists on clinically relevant levels of free serum ketorolac. Design: In vitro study. Setting: Pharmaceutics laboratory of a medical college. Interventions: The effect of 6{\%} hydroxyethylstarch, 5{\%} albumin, 6{\%} dextran 60, and lactated Ringer's solution on in vitro plasma protein binding of ketorolac was investigated by ultrafiltration. The binding was studied at three different drug concentrations: low therapeutic (0.3 μg/ml), high therapeutic (3 μg/ml), and toxic (10 μg/ml), and at two or more volume expander dilutions. Measurements and Main Results: The effect of plasma dilution on free ketorolac was consistent across all volume expanders tested and for each ketorolac concentration studied. As the plasma dilution with albumin, hydroxyethylstarch, dextran 60, or lactated Ringer's solution increased, the unbound ketorolac also increased from 3.2{\%} to 3.3{\%} in undiluted plasma to 5.0{\%} to 8.7{\%} in 50{\%} dilution of the plasma with the investigated expanders. Dilution of plasma by only 10{\%} resulted in a significant, but relatively minor, increase of unbound ketorolac to 3.2{\%} to 3.8{\%}. Conclusion: Because of the pharmacokinetic properties of ketorolac, this pharmacokinetic interaction can be expected to have only minor effects on unbound ketorolac concentrations when ketorolac is administered after the plasma expander. When ketorolac administration is followed by rapid plasma expander infusion, a transient increase of unbound ketorolac in plasma can be expected.",
keywords = "Albumin, Dextran 60, Hydroxyethylstarch, Ketorolac, Plasma, Protein binding, Ringer's solution, lactated",
author = "Dietrich Gravenstein and Ajit Suri and Derendorf, {Hartmut C.} and Adolph Koska",
year = "1998",
month = "9",
doi = "10.1016/S0952-8180(98)00064-6",
language = "English (US)",
volume = "10",
pages = "464--468",
journal = "Journal of Clinical Anesthesia",
issn = "0952-8180",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Influence of plasma expansion on plasma protein binding of ketorolac

AU - Gravenstein, Dietrich

AU - Suri, Ajit

AU - Derendorf, Hartmut C.

AU - Koska, Adolph

PY - 1998/9

Y1 - 1998/9

N2 - Study Objective: To determine the effect of dilution with intravascular volume expanders commonly used by anesthesiologists on clinically relevant levels of free serum ketorolac. Design: In vitro study. Setting: Pharmaceutics laboratory of a medical college. Interventions: The effect of 6% hydroxyethylstarch, 5% albumin, 6% dextran 60, and lactated Ringer's solution on in vitro plasma protein binding of ketorolac was investigated by ultrafiltration. The binding was studied at three different drug concentrations: low therapeutic (0.3 μg/ml), high therapeutic (3 μg/ml), and toxic (10 μg/ml), and at two or more volume expander dilutions. Measurements and Main Results: The effect of plasma dilution on free ketorolac was consistent across all volume expanders tested and for each ketorolac concentration studied. As the plasma dilution with albumin, hydroxyethylstarch, dextran 60, or lactated Ringer's solution increased, the unbound ketorolac also increased from 3.2% to 3.3% in undiluted plasma to 5.0% to 8.7% in 50% dilution of the plasma with the investigated expanders. Dilution of plasma by only 10% resulted in a significant, but relatively minor, increase of unbound ketorolac to 3.2% to 3.8%. Conclusion: Because of the pharmacokinetic properties of ketorolac, this pharmacokinetic interaction can be expected to have only minor effects on unbound ketorolac concentrations when ketorolac is administered after the plasma expander. When ketorolac administration is followed by rapid plasma expander infusion, a transient increase of unbound ketorolac in plasma can be expected.

AB - Study Objective: To determine the effect of dilution with intravascular volume expanders commonly used by anesthesiologists on clinically relevant levels of free serum ketorolac. Design: In vitro study. Setting: Pharmaceutics laboratory of a medical college. Interventions: The effect of 6% hydroxyethylstarch, 5% albumin, 6% dextran 60, and lactated Ringer's solution on in vitro plasma protein binding of ketorolac was investigated by ultrafiltration. The binding was studied at three different drug concentrations: low therapeutic (0.3 μg/ml), high therapeutic (3 μg/ml), and toxic (10 μg/ml), and at two or more volume expander dilutions. Measurements and Main Results: The effect of plasma dilution on free ketorolac was consistent across all volume expanders tested and for each ketorolac concentration studied. As the plasma dilution with albumin, hydroxyethylstarch, dextran 60, or lactated Ringer's solution increased, the unbound ketorolac also increased from 3.2% to 3.3% in undiluted plasma to 5.0% to 8.7% in 50% dilution of the plasma with the investigated expanders. Dilution of plasma by only 10% resulted in a significant, but relatively minor, increase of unbound ketorolac to 3.2% to 3.8%. Conclusion: Because of the pharmacokinetic properties of ketorolac, this pharmacokinetic interaction can be expected to have only minor effects on unbound ketorolac concentrations when ketorolac is administered after the plasma expander. When ketorolac administration is followed by rapid plasma expander infusion, a transient increase of unbound ketorolac in plasma can be expected.

KW - Albumin

KW - Dextran 60

KW - Hydroxyethylstarch

KW - Ketorolac

KW - Plasma

KW - Protein binding

KW - Ringer's solution, lactated

UR - http://www.scopus.com/inward/record.url?scp=0032168162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032168162&partnerID=8YFLogxK

U2 - 10.1016/S0952-8180(98)00064-6

DO - 10.1016/S0952-8180(98)00064-6

M3 - Article

VL - 10

SP - 464

EP - 468

JO - Journal of Clinical Anesthesia

JF - Journal of Clinical Anesthesia

SN - 0952-8180

IS - 6

ER -